Avion Wealth’s Novavax NVAX Stock Holding History

Avion Wealth’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-325	Closed	-$2K	–	1468
2025 Q1	$2K	Hold	325	–	–	﹤0.01%	751
2024 Q4	$2K	Hold	325	–	–	﹤0.01%	748
2024 Q3	$4K	Hold	325	–	–	﹤0.01%	579
2024 Q2	$4K	Hold	325	–	–	﹤0.01%	521
2024 Q1	$2K	Hold	325	–	–	﹤0.01%	733
2023 Q4	$2K	Hold	325	–	–	﹤0.01%	595
2023 Q3	$2K	Buy	+325	New	+$2.6K	﹤0.01%	506
2023 Q2	–	Sell	-35	Closed	–	–	948
2023 Q1	$0	Buy	+35	New	+$322	﹤0.01%	704

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Avion Wealth's NVAX Position: Q2 2025 in Review

Avion Wealth sold out of Novavax (NVAX) in Q2 2025, closing a stake of 325 shares — an estimated $2K sold.

Avion Wealth first reported a position in NVAX in Q1 2023 and held it in 8 quarters. The position peaked at $4K in Q3 2024. 250 funds tracked by Wall St. Rank hold NVAX as of Q2 2025.

Avion Wealth reported no remaining Novavax position as of Q2 2025 after selling out during the quarter.
Avion Wealth sold 325 Novavax shares in Q2 2025, an estimated $2K.
Avion Wealth first reported a position in Novavax in Q1 2023 and held it in 8 quarters.
Avion Wealth's Novavax position peaked at $4K in Q3 2024.
250 funds tracked by Wall St. Rank held Novavax as of Q2 2025.

Based on Avion Wealth's 13F filing for Q2 2025, filed 25 Jul 2025.